Product Name:
FOXO1-pS319
Product Number:
ab-pn594
Target Full Name: Forkhead box protein O1
Target Alias: FKH1; FKHR; Forkhead box O1; Forkhead box O1A (FKHR); Forkhead box protein O1A; Forkhead in rhabdomyosarcoma; FOXO1
Product Type Specific: FOXO1A phosphosite-specific antibody
Antibody Code: PN594
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S319
Protein UniProt: Q12778
Protein SigNET: FOXO1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human FOXO1
Antibody Immunogen Sequence: PRTS(pS)NAS(βA)C
Antibody Immunogen Description: Corresponds to amino acid residues P315 to S322. S319 phosphorylation increases rate of nuclear exclusion. It also creates the pSer–Xaa–Xaa–Ser recognition motif for CK1, allowing it to phosphorylate S322, induces interaction with IQGAP1, and regulates apoptosis and inhibits transcription. This is one of the major in vivo phosphorylation sites in FOXO1A (≥30 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus). FOXO1A is known to be phosphorylated at this site in vitro by Akt1 (PKBa), Akt3 (PKBg), and SGK1.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus macaque | Dog | Rat | Mouse | Platypus | Zebra fish.
Related Product 1: FOXK1 S441+S445 phosphorylation antibody (Cat. No.: AB-PN590)
Related Product 2: FOXK2 S424+S428 phosphorylation antibody (Cat. No.: AB-PN591)
Related Product 3: FOXM1 T611 phosphorylation antibody (Cat. No.: AB-PN592)
Related Product 4: FOXO1 S256 phosphorylation antibody (Cat. No.: AB-PN593)
Related Product 5: FOXO1 S329 phosphorylation antibody (Cat. No.: AB-PN595)
Related Product 6: FOXO3 T32 phosphorylation antibody (Cat. No.: AB-PN596)
Related Product 7: FOXO3 S294 phosphorylation antibody (Cat. No.: AB-PN597)
Related Product 8: FOXO3 S253 phosphorylation antibody (Cat. No.: AB-PN821)
Scientific Background: FOXO1A (Forkhead box protein O1) is a key transcription factor and member of the O-class of forkhead box transcription factors. It plays a crucial role in regulating metabolism (gluconeogenesis, adipogenesis), cell proliferation, apoptosis, and oxidative stress responses. As a primary target of insulin signaling, its activity is inhibited by AKT-mediated phosphorylation, causing it to relocate from the nucleus to the cytoplasm. It promotes gluconeogenesis in the liver and plays a major role in regulating energy homeostasis, with its dysfunction linked to diabetes, obesity, and fatty liver disease. It regulates osteoblast numbers and controls bone mass. It acts synergistically with ATF4 to suppress osteocalcin/BGLAP activity, increasing glucose levels and triggering glucose intolerance and insulin insensitivity. lt suppresses the transcriptional activity of RUNX2, an upstream activator of osteocalcin/BGLAP. FOXO1A binds to the insulin response element (IRE) with consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3'. Insulin suppresses FOXO1A transcription activity. Its activity is tightly controlled by post-translational modifications, including phosphorylation (by AKT, CDK1), acetylation (by Sirt1/2), and ubiquitination. FOXO1 acts as a tumour suppressor by controlling cell cycle inhibitors (e.g., p21) and promoting apoptosis in various cancers. FOXO1 is expressed in multiple tissues, including skeletal muscle, liver, and adipose tissue. This description may include information annotated by UniProt and/or Google AI.